Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab-Reference-Cited by-同舟云学术

Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

Published:2012-07-27 Issue:8 Volume:64 Page:2719-2723
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Shapira Iuliana,Andrade Danieli,Allen Steven L.,Salmon Jane E.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference15 articles.

1. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients;Cervera;Arthritis Rheum,2002

2. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors;Espinosa;Semin Thromb Hemost,2008

3. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment;Asherson;Semin Thromb Hemost,2008

4. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome;Girardi;J Clin Invest,2003

5. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia;Pierangeli;Arthritis Rheum,2005

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical aspects of antiphospholipid syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Antiphospholipid syndrome in children;Best Practice & Research Clinical Rheumatology;2024-08

3. Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults;Journal of Clinical Medicine;2024-05-23

4. Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature;Rheumatology International;2024-03-19

5. Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria;Antibodies;2024-03-12